Stem Cell Clinic

Autologous Stem Cell and Non-Stem Cell Based Therapies MARKET 2020 |INDUSTRY ANALYSIS, SIZE, SHARE, TRENDS, MARKET DEMAND, GROWTH, OPPORTUNITIES AND…

This report focuses on the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

The latest research report on Autologous Stem Cell and Non-Stem Cell Based Therapies market encompasses a detailed compilation of this industry, and a creditable overview of its segmentation. In short, the study incorporates a generic overview of the Autologous Stem Cell and Non-Stem Cell Based Therapies market based on its current status and market size, in terms of volume and returns. The study also comprises a summary of important data considering the geographical terrain of the industry as well as the industry players that seem to have achieved a powerful status across the Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Get Sample of this Premium Report @ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=148458&RequestType=Sample

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Segmentation

By Type Autologous Stem Cell, Non-Stem Cell,

By Application Medical Centers and Universities, Clinical Laboratories,

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Competitive Landscape This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2020.

The major players in the market ANTRIA (CRO) (U.S.), BIOHEART (U.S.), BRAINSTORM CELL THERAPEUTICS (U.S.), CYTORI (U.S.), DENDREON CORPORATION (U.S.), FIBROCELL (U.S.), GENESIS BIOPHARMA (U.S.), GEORGIA HEALTH SCIENCES UNIVERSITY (U.S.), NEOSTEM (U.S.), OPEXA THERAPEUTICS (U.S.), ORGENESIS (U.S.), REGENEXX (U.S.), REGENEUS (AUSTRALIA), TENGION (U.S.), TIGENIX (BELGIUM), VIRXSYS (U.S.)

Global Autologous Stem Cell and Non-Stem Cell Based Therapies MarketThis research report providesCOVID-19 Outbreakstudy accumulated to offer Latest insights about acute features of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The report contains different market predictions related to marketsize, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary andSWOT analysis.It presents the360-degreeoverview of the competitive landscape of the industries. Autologous Stem Cell and Non-Stem Cell Based Therapies Market is showing steadygrowthandCAGRis expected to improve during the forecast period.

The main sources are industry experts from the global Autologous Stem Cell and Non-Stem Cell Based Therapies industry, including management organizations, processing organizations, and analytical services providers that address the value chain of industry organizations. We interviewed all major sources to collect and certify qualitative and quantitative information and to determine future prospects. The qualities of this study in the industry experts industry, such as CEO, vice president, marketing director, technology and innovation director, founder and key executives of key core companies and institutions in major biomass waste containers around the world in the extensive primary research conducted for this study We interviewed to acquire and verify both sides and quantitative aspects.

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Regional Analysis The report offers in-depth assessment of the growth and other aspects of the Autologous Stem Cell and Non-Stem Cell Based Therapies market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

Do You Have Any Query Or Specific Requirement @https://brandessenceresearch.biz/Request/Sample?ResearchPostId=148458&RequestType=Methodology

Complete Analysis of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market:

Comprehensive assessable analysis of the industry is provided for the period of 2020-2025 to help investors to capitalize on the essential market opportunities.

The key findings and recommendations highlight vital progressive industry trends in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market, thereby allowing players to improve effective long term policies

A complete analysis of the factors that drive market evolution is provided in the report.

To analyze opportunities in the market for stakeholders by categorizing the high-growth segments of the market

The numerous opportunities in the Autologous Stem Cell and Non-Stem Cell Based Therapies market are also given.

Report Answers Following Questions:

What are the factors driving the growth of the market?

What factors are inhibiting market growth?

What are the future opportunities in the market?

Which are the most dynamic companies and what are their recent developments within the Autologous Stem Cell and Non-Stem Cell Based Therapies Market?

What key developments can be expected in the coming years?

What are the key trends observed in the market?

TABLE OF CONTENT

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Read Full Report: https://brandessenceresearch.biz/Lifesciences-and-Healthcare/Global-and-Regional-Autologous-Stem-Cell-and-Non-Stem-Cell-Based-Therapies-Industry-Production-Sales-and-Consumption-Status-and-Prospects-Professional-Market-Research-Report/Summary

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Blog: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog:https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Blog:https://tcbiznews.com/

Top Trending Reports:

https://www.marketwatch.com/press-release/cardiac-rhythm-management-device-market-2020-global-analysis-opportunity-and-forecast-to-2025-2020-09-24?tesla=y

https://www.marketwatch.com/press-release/automotive-transmission-market-size-segmented-by-product-type-top-manufacturers-by-end-user-industry-geography-trends-and-forecast-2025-2020-09-24?tesla=y

https://www.marketwatch.com/press-release/at-103-cagr-amniotic-membrane-market-size-to-surpass-usd-18003-million-by-2025-2020-09-24?tesla=y

https://www.marketwatch.com/press-release/biomarkers-market-growing-at-a-cagr-of-141-global-industry-research-on-growth-trends-and-opportunity-2020-2025-2020-09-24?tesla=y

https://www.marketwatch.com/press-release/antimony-market-2020-cagr-of-612-with-top-countries-data-latest-trends-market-size-share-industry-analysis-and-forecast-to-2025-2020-09-24?tesla=y

Read more here:
Autologous Stem Cell and Non-Stem Cell Based Therapies MARKET 2020 |INDUSTRY ANALYSIS, SIZE, SHARE, TRENDS, MARKET DEMAND, GROWTH, OPPORTUNITIES AND...

Finding The Achilles Heel of A Killer Parasite – Newswise

Newswise DALLAS Sept. 24, 2020 Two studies led by UT Southwestern researchers shed light on the biology and potential vulnerabilities of schistosomes parasitic flatworms that cause the little-known tropical disease schistosomiasis. The findings, published online today in Science, could change the course of this disease that kills up to 250,000 people a year.

About 240 million people around the world have schistosomiasis mostly children in Africa, Asia, and South America in populations that represent the poorest of the poor, says study leader James J. Collins III, Ph.D., associate professor in UTSWs department of pharmacology.

Most of those infected survive, but those who die often suffer organ failure or parasite-induced cancer. Symptoms can be serious enough to keep people from living productive lives, Collins says.

The parasite that causes this disease has a complicated life cycle that involves stages in both freshwater snails and mammals. Dwelling in mammalian hosts circulatory systems, schistosomes feed on blood and lay copious numbers of eggs, all while causing an array of symptoms including abdominal pain, diarrhea, bloody stool, or blood in the urine. Larval worms are released from snails into water, where the flatworms then may infect humans by penetrating the skin. Schistosomiasis may become a chronic disease that affects the person for years.

Only one drug, praziquantel, is available to treat this condition. However, Collins explains, it is of limited use it doesnt kill all intramammalian stages of the schistosome life cycle, and it has a variable cure rate in some endemic settings. Theres been little interest by pharmaceutical companies in developing new drugs for this disease, he adds, because there is no monetary incentive to do so. Consequently, relatively few studies have been devoted to understanding schistosomes basic biology, which might reveal inherent weaknesses that could serve as targets for new drugs.

To that end, Collins and his colleagues embarked upon two separate studies one at the cellular level and another at the molecular level to better understand these organisms.

In the first study, the researchers delved into the cell types that make up these flatworms. Although the worms are multicellular organisms composed of a variety of unique tissue types, researchers knew little about the different cell populations in these parasites.

With a goal to create an atlas of cell types in Schistosoma mansoni one of the schistosome species that commonly causes schistosomiasis Collins and his team used a technique called single-cell RNA sequencing that distinguishes individual cell types based on their unique gene expression patterns. With this method, they identified 68 molecularly unique clusters of cells, including a population of stem cells that form the gut. When the researchers used a targeted approach called RNA interference (RNAi) to shut down the activation of a key gene in these cells, the resulting worms couldnt digest red blood cells a key to their growth and a pivotal part of the pathology they cause.

In the second study, the researchers used RNAi to sort out the function of about 20 percent of S. mansonis protein coding genes 2,216 in total. Previously, only a handful of genes in these organisms had been assessed.

By deactivating the genes one by one, Collins and his colleagues identified more than 250 genes crucial for survival. Using a database of pharmacological compounds, the researchers then searched for drugs that had the potential to act on proteins produced by these genes, identifying several compounds with activity on worms. The team also uncovered two protein kinases a group of proteins renowned for their ability to be targeted by drugs that are essential for muscle function. When these kinases were inhibited, the worms became paralyzed and eventually died, suggesting that drugs targeting these proteins could eventually treat people with schistosomiasis. A next step in the research will be to search for inhibitors of these proteins.

Collins notes that these strides in understanding the basic biology of schistosomes could eventually lead to new treatments to save untold lives in places where schistosomiasis is endemic.

This is a very important disease that most people have never heard of, he says. We need to invest and invigorate research on these parasites.

UTSW researchers who contributed to the first study include George Wendt, Lu Zhao, Rui Chen, and Michael L. Reese. UTSW researchers who contributed to the second study include Jipeng Wang, Carlos Paz, Irina Gradinaru, and Julie N. R. Collins.

The first study was supported by grants from the National Institutes of Health (R01 R01AI121037, R01 R01AI150715, R21 R21AI133393, and F30 1F30AI131509-01A1, the Welch Foundation (I-1948-20180324 and I-1936-20170325), the National Science Foundation (MCB1553334), the Burroughs Wellcome Fund, the Wellcome Trust (107475/Z/15/Z), and the Bill and Melinda Gates Foundation (OPP1171488).

The second study was supported by grants from the National Institutes of Health (R01AI121037), the Welch Foundation (I-1948-20180324), the Burroughs Wellcome Fund, and the Wellcome Trust (107475/Z/15/Z and 206194).

James Collins is Rita C. and William P. Clements, Jr. Scholar in Biomedical Research.

About UTSouthwestern Medical Center

UTSouthwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 23 members of the National Academy of Sciences, 16 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.

Read the original post:
Finding The Achilles Heel of A Killer Parasite - Newswise

SHE Initiative Shines Light on Gender Disparities in Oncology Workforce – Targeted Oncology

The Association of Community Cancer Centers (ACCC) National Oncology Conference each year helps community oncologists approach both unique and typical challenges with innovative strategies. This year, one of the challenges addressed that has been increasingly raised throughout the year was the topic of disparities in the medical field.

To close out the ACCC 37th (Virtual) National Oncology Conference, keynote speaker Nick Smith-Stanley, MBA, addressed the topic of diversity and inclusion for women in medicine, and specifically in the field of oncology.

Smith-Stanley, associate director of finance and administration, Livestrong Cancer Institutes, Dell Medical School, associate director of administration and strategic planning, Department of Oncology, Dell Medical School, The University of Texas at Austin, explained the challenges faced by women in the oncology workplace and quantified the divide seen between the number of men and women in oncology and in positions of leadership in the medical field.

By discussing the lack of women in the field of oncology, he said, it will hopefully lead to developing strategies that address such challenges, which can then lead to real change.

He also presented how the Livestrong Cancer Institutes Dell Medical School has created a program that seeks to address this gap and give the future generation of women in medicine the tools they need to succeed.

The Growing Gender Divide Across a Medical Career Span

Oncology is known to be a male-dominated field in the healthcare space. Although the number of female students and physicians in the field has grown over the past few years, the proportion of women compared to men in medicine is still less than half. Further, the numbers get lower throughout the continuum of a medical career from medical student to physician to professor and then dean.

Smith-Stanley said that, encouragingly, for the first time in history, the number of female medical students is higher than the number of male students, but the difference is marginal. The rates decrease, however, over the course of a medical career. The number of female residents and fellows is below 50% and has not changed much in the last 10 years, and specific to oncology and hematology, the proportion of female residents and fellows is below about 45%.

Among practicing physicians, only 35% are female, and within the oncology/hematology field specifically, the rate is closer to one-third. However, this is increased from 10 years ago when the rate of female physicians was only about 28% overall and about 25% in the oncology field.

Within research in general, as of 2018, 50% of STEM (science, technology, engineering, and mathematics) positions were held by women, but specifically to science and engineering, only 28% of women hold positions in these fields.

Across all disciplines in science and oncology, we see women struggling to be considered for opportunities for promotion and leadership, Smith-Stanley said. One faculty member at Dell Medical School told us that throughout her career she has seen male colleagues with fewer accomplishments get promoted at the same time. In addition, she shared that at previous institutions, rules were not as rigid for promotion and tenure for men as they were for women, they were willing to bend the rules for men, but not for women. This shows that this is not only a personal or organizational issue, it is by far a systemic issue.

He pointed out that as a result, women hold fewer positions of leadership than men. Only 19% of department chairs were held by women in the year 2019 and only 21% of full professors are female.

This poses a greater problembecause of the lack of mentorship opportunities. If our students and junior faculty are unable to identify women in positions of leadership and mentorship to help guide their career then they are less likely to progress in their career as well, he commented.

He suggested that these rates reduce across the span of a medical career due to a lack of tools, mentorship, and support given to women in medicine.

Smith-Stanley offered some strategies to bridge the gender divide through organizational changes. Starting with culture, organizational leaders must embrace and promote an all-inclusive environment. Training on diversity and bias is one way to overcome these barriers and allow for change. Providing opportunities for professional development, including mentorship and networking, can also help to retain the women in the medical workforce.

Livestrong Cancer Institutes, he said, is one of the few cancer centers across the country that is led by a woman, S. Gail Eckhardt, MD, who is the director and associate dean of cancer programs at the company. As such, Dell Medical School is focused on addressing such healthcare disparities and leaders at the Livestrong Cancer Institutes feel that they have a responsibility to address the role that women play in cancer, research, and academics.

SHE Takes a Step Towards Overcoming Gender Disparities

The Livestrong Cancer Institute stressed the use of early education and mentorship to bridge the gender gap, which ultimately led to the development of the Summer Healthcare Experience (SHE) program in oncology. SHE is a free, immersive week-long program for introducing female-identifying high school juniors and seniors to a range of career opportunities in the cancer field. The program was launched in the summer of 2019 when 8 young women from Austin were selected with health program teachers and brought to the Dell Medical School to learn more about the various careers involved with cancer care.

The SHE program sought to empower young women to take control of their education and future careers by giving them tools to overcome challenges in the workplace. The high school students were given the opportunity to participate in research and interact with the clinical teams. Participating students also came away with a general knowledge of cancer, how it is treated, and the challenges that patients with cancer and their caregivers face. Additionally, the program promoted leadership skills and professionalism that could be used throughout their career, no matter the field.

During the week, the students worked with women in the cancer center to learn about cancer anatomy and how physicians work together for the care of patients with cancer. In the wet research lab, the students were able to see cell cultures and tumor slides and they also investigated different brain tumors in the neuro-oncology lab. The students were also able to join in on the molecular tumor boards to see the interaction between various departments for deciding on optimal care for a patient. In a survivorship session, the students were also able to meet with cancer survivors and their families and learn about their cancer journeys. Additionally, the students learned about health services research in the community and how health services researchers are investigating healthcare disparities in patients with cancer.

Throughout the week, the students were able to interact with female leaders from the cancer center, including center director Eckhardt, to hear about and learn from their experiences and the challenges they faced in their careers. They also met with a number of community organizations, from American Cancer Society to the Austin Center for Grief and Loss, to hear about how these organizations are assisting patients with cancer in the city.

Its not enough to just talk about equity and inclusion. You need to have people who are invested in the conversation and the desire to make a difference. Thats exactly what we saw in the first year of SHE, Smith-Stanley said.

The students were tasked with coming up with a comprehensive care plan for a cancer case based on all they learned during the week. These plans were then presented at the end of the week to faculty from Livestrong Cancer Institutes, Dell Medical Center, the students high school teachers, and their families.

We could not have been more thrilled with the results. They were confident, they were thoughtful, they were knowledgeable, they were compassionate. The transformation that we witnessed from Monday to Friday was remarkable, Smith-Stanley commented.

Moving forward, the Livestrong Cancer Institutes hopes to expand the SHE program to more students and extend the program to 2 weeks. The program also hopes to add in more biomedical research, entrepreneurship education, a college prep day, and even a post-program internship. Livestrong Cancer Institutes is also partnering with other organizations to spread the SHE program to 4 other cancer centers, and hopefully nationwide, although this expansion has been delayed by the coronavirus disease 2019.

Reference

Smith-Stanley N. Addressing the Disparities of Women in Oncology. Presented at: ACCC National Oncology Conference; September 14-18, 2020; Virtual.

Read more:
SHE Initiative Shines Light on Gender Disparities in Oncology Workforce - Targeted Oncology